Asset Turnover measures how quickly a company turns over its asset through sales. It is calculated as Revenue divided by Total Assets. MaxCyte's Revenue for the
three
months ended in Mar. 2026 was $9.65 Mil. MaxCyte's Total Assets for the quarter that ended in Mar. 2026 was $198.49 Mil. Therefore, MaxCyte's Asset Turnover for the quarter that ended in Mar. 2026 was 0.05.
Asset Turnover is linked to ROE % through Du Pont Formula. MaxCyte's annualizedROE % for the quarter that ended in Mar. 2026 was -11.20%. It is also linked to ROA % through Du Pont Formula. MaxCyte's annualizedROA % for the quarter that ended in Mar. 2026 was -9.57%.
MaxCyte (NAS:MXCT) Asset Turnover Explanation
Asset Turnover is linked to ROE % through Du Pont Formula.
MaxCyte's annulizedROE % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
** The ROE % used above is for Du Pont Analysis only. It is different from the defined ROE % page on our website, as here it uses Net Income instead of Net Income attributable to Common Stockholders in the calculation.
It is also linked to ROA % through Du Pont Formula:
MaxCyte's annulizedROA % for the quarter that ended in Mar. 2026 is
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Therefore, it is a good sign if a company's Asset Turnover is consistent or even increases. If a company's asset grows faster than sales, its Asset Turnover will decline, which can be a warning sign.
MaxCyte Asset Turnover Related Terms
MaxCyte Asset Turnover Historical Data
* Premium members only.
The historical data trend for MaxCyte's Asset Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MXCT vs RCEL, NNOX, SNWV: Asset Turnover Comparison
For the Medical Devices subindustry, MaxCyte's Asset Turnover, along with its competitors' market caps and Asset Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
MaxCyte Asset Turnover vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, MaxCyte's Asset Turnover distribution charts can be found below:
* The bar in red indicates where MaxCyte's Asset Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Companies with low profit margins tend to have high Asset Turnover, while those with high profit margins have low Asset Turnover. Companies in the retail industry tend to have a very high turnover ratio.
MaxCyte (MXCT) has a Asset Turnover of 0.05 as of Mar. 2026. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on MaxCyte and its competitors.
Is MaxCyte's Asset Turnover too high?
MaxCyte's current Asset Turnover is 0.05. Overall, MaxCyte has a GF Score™ of 62/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does MaxCyte's Asset Turnover compare to RCEL and NNOX?
MaxCyte's Asset Turnover of 0.05 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Asset Turnover for a Medical Devices & Instruments company?
A good Asset Turnover depends on the Medical Devices & Instruments industry context. However, Asset Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Asset Turnover mean?
A high Asset Turnover can signal that a stock is expensive relative to its fundamentals. Asset turnover equals current-period sales over average total assets over the past two periods. View historical data on MaxCyte and its competitors. MaxCyte's current Asset Turnover is 0.05. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MaxCyte stock overvalued right now?
Based on GuruFocus' analysis, MaxCyte (MXCT) is currently considered Possible Value Trap. The stock's GF Value™ is $2.57, compared to a current price of $1.27 — trading 50.6% below its estimated fair value. The current Asset Turnover is 0.05. MaxCyte's overall GF Score™ is 62/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Asset Turnover calculated?
Asset Turnover is calculated from a company's financial statements. For MaxCyte (MXCT), the current Asset Turnover is 0.05 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MaxCyte (MXCT) Overvalued in 2026?
Based on GuruFocus' analysis, MaxCyte stock appears to be undervalued.
The current stock price of $1.27 is trading 50.6% below its estimated GF Value™ of $2.57.
GuruFocus considers MaxCyte to be Possible Value Trap.
Key valuation signals for MXCT:
Asset Turnover: 0.05
GF Value™: $2.57 vs. price of $1.27 (50.6% below fair value)
No single metric tells the full story. See the MXCT stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.
62GF Score
Get the complete analysis for MXCT
Asset Turnover is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MXCT has been successfully added to your 
